Compare Amgen, Inc. (AMGN) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Rush Street Interactive Inc — how do they compare? Amgen, Inc. trades at $417.37 (market cap $224.14B), while Rush Street Interactive Inc trades at $24.57 (market cap $2.91B). The key difference: Amgen, Inc. is far larger — about 77× Rush Street Interactive Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| AMGN | RSI | |
|---|---|---|
Market Cap | $224.14B | $2.91B |
Sector | Health | Technology |
52-Week High | $417.20 | $34.52 |
52-Week Low | $271.18 | $15.89 |
Enterprise Value | $267.45B | $2.57B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Rush Street Interactive (RSI) trades at $24.53, down 0.77% on the day, amid mixed technical signals with a bearish overall trend but oversold oscillators. The company reported strong Q2 2026 results with record revenue of $393.8 million and raised full-year guidance, though net margins remain thin at 2.33%. Analyst sentiment remains bullish with 77% buy ratings and a $34.75 consensus target.
RSI shows promising revenue growth and institutional interest but faces valuation concerns with a high P/E of 81.13. The stock offers significant upside to analyst targets but requires careful monitoring of margin expansion and competitive pressures in the online gambling sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
